CD4+ T lymphocyte counts after autologous transplantation in multiple myeloma: a retrospective study.

abstract：:Twenty-nine patients with non-Hodgkin's lymphoma received a single subcutaneous injection of 6 mg pegfilgrastim approximately 24 h after the start of CHOP chemotherapy. The safety of pegfilgrastim in this patient population was determined by reports of adverse events. The pharmacokinetics of pegfilgrastim were charact...

journal_title：Leukemia & lymphoma

authors： George S,Yunus F,Case D,Yang BB,Hackett J,Shogan JE,Meza LA,Neumann TA,Liang BC

更新日期：2003-10-01 00:00:00

abstract：:In the present study we assess the antitumor effect and circulating stem cells (CSC) mobilizing capacity of high-dose cyclophosphamide (5 to 7 gr/m2, HDCY). This treatment was given to 21 patients with various hematologic malignancies (8 NHL, 5 MM, 4 HD, 3 CML) excluding 1 with neuroblastoma. All were eligible for lat...

journal_title：Leukemia & lymphoma

authors： Indovina A,Majolino I,Scimè R,Vasta S,Gentile S,Liberti G,Santoro A,Pampinella M,Caronia F

更新日期：1994-06-01 00:00:00

abstract：:The fusion toxin DT388IL3 composed of the catalytic and translocation domains of diphtheria toxin (DT388) linked to interleukin-3 (IL3) was administered to 6 cynomolgus monkeys which possessed cross-reactive IL3 receptors. Groups of 2 animals (1 male and 1 female) received up to 6 every other day slow intravenous infu...

journal_title：Leukemia & lymphoma

authors： Cohen KA,Liu TF,Cline JM,Wagner JD,Hall PD,Frankel AE

更新日期：2004-08-01 00:00:00

abstract：:One-hundred-and-thirty typical, unselected CLL cases were studied by conventional cytogenetic analysis. Seventy-three patients (56.2%) had normal karyotype ('normal sub-group'), while 57/130 patients (43.8%) had abnormal karyotype. Twenty-two of 57 patients (38.6%) carried more than one abnormality. Six novel chromoso...

journal_title：Leukemia & lymphoma

authors： Athanasiadou A,Stamatopoulos K,Tsezou A,Vadikolia C,Asteriou O,Fassas A,Anagnostopoulos A

更新日期：2006-10-01 00:00:00

abstract：:Patients with CTCL are at increased risk for bacteremia which is a leading cause of morbidity and mortality. We assessed risk factors for and the impact of bacteremia on survival in a retrospective cohort of 188 CTCL patients at a single US academic institution treated between 1990 and 2018. With a median follow up of...

journal_title：Leukemia & lymphoma

authors： Allen PB,Switchenko J,Ayers A,Kim E,Lechowicz MJ

更新日期：2020-11-01 00:00:00

abstract：:The classification of germinal centre (GC) and non-GC is an important prognostic immunophenotype for patients with diffuse large B cell lymphoma (DLBCL) following anthracycline-based chemotherapy. The expression of the anti-apoptotic protein, Bcl-2, has been associated with an unfavourable prognosis in patients with D...

journal_title：Leukemia & lymphoma

authors： Song MK,Chung JS,Shin DH,Seol YM,Shin HJ,Choi YJ,Cho GJ

更新日期：2009-01-01 00:00:00

abstract：:Monitoring of t(14;18) in blood or bone marrow in follicular lymphoma (FL) remains controversial. We attempted to monitor t(14;18) in lymph nodes by ultrasound-guided fine needle aspirations (UG-FNA). First, we confirmed t(14;18) in 27/31 UG-FNAs of lymph nodes with fluorescent in situ hybridisation (FISH) and/or poly...

journal_title：Leukemia & lymphoma

authors： Janikova A,Mayer J,Kren L,Smardova J,Dvorakova D,Neubauer J,Vasova I

更新日期：2009-07-01 00:00:00

abstract：:Vasculitis may accompany neoplasias and be of paraneoplastic type or associated with drugs used in patient treatment. We evaluated skin biopsies of twenty-eight cases with vasculitis accompanying leukemias reviewed and clinical outcome was evaluated. Eleven of the 28 cases had paraneoplastic vasculitis and 17 had vasc...

journal_title：Leukemia & lymphoma

authors： Paydaş S,Zorludemir S,Sahin B

更新日期：2000-12-01 00:00:00

abstract：:The induction of apoptosis following topoisomerase inhibitors proceeds in at least three distinct steps: (1) induction of cleavable complexes (potentially lethal damage), (2) topoisomerase-induced DNA damage, and (3) a presently unknown sequence of events that must either lead to cell cycle arrest (G2-block, different...

journal_title：Leukemia & lymphoma

authors： Solary E,Bertrand R,Pommier Y

更新日期：1994-09-01 00:00:00

abstract：:We report follow-up information on 69 hairy cell leukemia (HCL) patients treated with interferon alfa-2b (IFN) as primary treatment from 1983 to 1986. Follow-up through April, 1993 shows that only 14 patients have expired. Forty-seven of the 61 patients completing the intended 12 or more months of initial IFN treatmen...

journal_title：Leukemia & lymphoma

authors： Spielberger RT,Mick R,Ratain MJ,Golomb HM

更新日期：1994-01-01 00:00:00

abstract：:Loss of function of the ataxia-telangiectasia mutated (ATM) gene, located on human chromosome 11q22-23, is the cause of ataxia-telangiectasia (A-T), which is associated with an extremely high risk for lymphoma. Abnormalities in 11q22-23, including deletions and mutations of the ATM gene, have been reported in T-cell p...

journal_title：Leukemia & lymphoma

authors： Lossos IS,Thorstenson YR,Wayne TL,Oefner PJ,Levy R,Chu G

更新日期：2002-05-01 00:00:00

abstract：:The c-mpl gene encodes a member of the hematopoietic cytokine receptor superfamily. This gene was discovered through the study of a murine retrovirus which induces an acute myeloproliferative syndrome in mice. MPLV (for myeloproliferative leukemia virus) has transduced a truncated and constitutively activated form of ...

journal_title：Leukemia & lymphoma

authors： Bouscary D,Prudhomme C,Quesnel B,Melle J,Picard F,Dreyfus F

更新日期：1995-03-01 00:00:00

abstract：:Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders of the elderly that carry an increased risk of progression to acute myeloid leukemia (AML). Since small non-coding RNAs (sRNAs), including microRNA (miRNAs), act as regulators of cellular differentiation, we hypothesized that changes to sRNAs might be ...

journal_title：Leukemia & lymphoma

authors： Guo Y,Strickland SA,Mohan S,Li S,Bosompem A,Vickers KC,Zhao S,Sheng Q,Kim AS

更新日期：2017-09-01 00:00:00

abstract：:Chronic myelogenous leukaemia (CML) is one of the most intensively studied human malignancies. It has been the focus of major efforts to develop potent drugs for several decades, but until recently cure rates remained low. A breakthrough in CML therapy was very likely accomplished with the clinical introduction of STI...

journal_title：Leukemia & lymphoma

authors： Feller SM,Tuchscherer G,Voss J

更新日期：2003-03-01 00:00:00

abstract：:Abstract Reconstitution, engraftment kinetics and tumor cell clearance were analyzed after reduced intensity conditioning hematopoietic cell transplant (RIC-HCT) in patients with chronic lymphocytic leukemia (CLL). Patients were transplanted from unrelated (n = 40) or related (n = 10) donors after fludarabine and 2 Gy...

journal_title：Leukemia & lymphoma

authors： Hebenstreit K,Iacobelli S,Leiblein S,Eisfeld AK,Pfrepper C,Heyn S,Vucinic V,Franke GN,Krahl R,Fricke S,Becker C,Pönisch W,Behre G,Niederwieser D,Lange T

更新日期：2014-06-01 00:00:00

abstract：:Although the recognition of hybrid acute leukemia (HAL) is still controversial, several reports have described cytogenetic findings in these leukemias over the last 3 years. A distinct chromosomal profile appears to be associated with different immunologic subsets of HAL. The classical t(15;17), and inv(16) as well as...

journal_title：Leukemia & lymphoma

authors： Cuneo A,Boogaerts M,Ferrant A,Michaux JL,Bosly A,Louwagie A,Van den Berghe H,Balsamo R,Roberti G,Bardi A

更新日期：1995-01-01 00:00:00

abstract：:Syndecan-1 is a transmembrane proteoglycan expressed on the surface of tumor cells of various origins including myeloma, Hodgkin's disease, and certain human immunodeficiency virus (HIV) associated lymphomas. Functional studies in myeloma reveal that syndecan-1 may act as a multifunctional regulator of cell behavior i...

journal_title：Leukemia & lymphoma

authors： Dhodapkar MV,Sanderson RD

更新日期：1999-06-01 00:00:00

abstract：:We report a 50-year-old patient with idiopathic hypereosinophilic syndrome with trisomy 8 who experienced a complete and durable hematological and cytogenetic remission with low-dose imatinib therapy. He also had a significant reversal of cardiac dysfunction with a reduction in cardiac hypertrophy, resolution of peric...

journal_title：Leukemia & lymphoma

authors： Onitilo AA,Kio EA,Singh AK,Lazarchick J

更新日期：2005-11-01 00:00:00

abstract：:The importance of obtaining a tumor-free graft for autologous transplantation in cancer patients has been debated extensively in the last decade and is still unresolved largely because it is believed that relapse is more likely to originate from the host and not from the graft. This is in spite of recent indications t...

journal_title：Leukemia & lymphoma

authors： Gazitt Y,Reading CL

更新日期：1996-10-01 00:00:00

abstract：:There are limited effective therapies for most patients with relapsed diffuse large B-cell lymphoma (DLBCL). We conducted a phase II trial of the multi-targeted vascular endothelial growth factor receptor (VEGFR) kinase inhibitor, sunitinib, 37.5 mg given orally once daily in adult patients with relapsed or refractory...

journal_title：Leukemia & lymphoma

authors： Buckstein R,Kuruvilla J,Chua N,Lee C,Macdonald DA,Al-Tourah AJ,Foo AH,Walsh W,Ivy SP,Crump M,Eisenhauer EA

更新日期：2011-05-01 00:00:00

abstract：:The pattern of disease relapse in nine patients with multiple myeloma who had received double hemi body irradiation therapy is analysed. This analysis highlights the localisation of these relapses to skeletal areas excluded from initial radiation fields. This phenomenon was also documented in a patient who received sy...

journal_title：Leukemia & lymphoma

authors： Giles FJ,Lord CD,Gaminarai EJ,Grants IR,Kearney JW,Mills MJ,Newland AC,Nikoskelainen J,Pelliniemi T,Richards JD,Rostom AC,Tobias JS,Trask CT,Goldstone AH

更新日期：1990-01-01 00:00:00

abstract：:Respiratory viral pathogens are a common cause of morbidity in patients with hematologic malignancies. Sensitive molecular assays have increased the detection of common respiratory viruses and expanded the panel of detectable viruses. Both a rapid viral culture with direct fluorescence antibody (DFA) staining and a PC...

journal_title：Leukemia & lymphoma

authors： Murali S,Langston AA,Nolte FS,Banks G,Martin R,Caliendo AM

更新日期：2009-04-01 00:00:00

abstract：:The management of lymphoma in patients with primary immunodeficiency (PID) is challenging because of its poor prognosis and complex therapeutic approaches. We conducted a systematic literature review of case-reports, case-series, and cohorts indexed in MEDLINE reporting the association of lymphoma and PID. One hundred...

journal_title：Leukemia & lymphoma

authors： Herber M,Mertz P,Dieudonné Y,Guffroy B,Jung S,Gies V,Korganow AS,Guffroy A

更新日期：2020-02-01 00:00:00

abstract：:This study reports an autopsy case of a 53 year-old male with rapidly progressive extra-nodal NK/T-cell lymphoma accompanied with unusual clinical and pathologic features. He was initially presented with localized swelling and tenderness in the right lower extremity and the biopsy from the calf muscle was interpreted ...

journal_title：Leukemia & lymphoma

authors： Min HS,Hyun CL,Paik JH,Jeon YK,Choi G,Park SH,Seo JW,Kim CW

更新日期：2006-02-01 00:00:00

abstract：:Treatment of hairy cell leukemia (HCL), a disease first described in 1958, has evolved from splenectomy, which resulted in a normalization of blood counts in about 41% of patients and an improvement in the remaining 59% of patients but with a time to failure of only approximately 19 months, through treatment in the ea...

journal_title：Leukemia & lymphoma

authors： Golomb HM

更新日期：2011-06-01 00:00:00

abstract：:Speed of response to therapy predicts outcome in childhood lymphoblastic leukaemia. This observation has been made studying both blood and bone marrow in children on widely differing treatment regimens from the 1970s to the present day. It appears to be independent of other classical prognostic factors such as age and...

journal_title：Leukemia & lymphoma

authors： Lilleyman JS

更新日期：1998-11-01 00:00:00

abstract：:This single institution cohort study of 132 AML patients investigated the clinical implications of co-mutations detected with a 42-gene NGS panel. In the intermediate-risk cytogenetic group, FLT3-ITD is an adverse prognostic indicator only in the presence of a DNMT3A co-mutation, regardless of NPM1 mutation status. In...

journal_title：Leukemia & lymphoma

authors： Ma J,Dunlap J,Paliga A,Traer E,Press R,Shen L,Fan G

更新日期：2018-08-01 00:00:00

abstract：:It is generally accepted that allogeneic stem cell transplantation can 'cure' chronic myelogenous leukemia (CML), although occasional patients relapse more than 10 years after the transplant procedure. Such cures presumably result from the combined effects of leukemia stem cells (LSCs) of the conditioning regimen and ...

journal_title：Leukemia & lymphoma

authors： Goldman J,Gordon M

更新日期：2006-01-01 00:00:00

abstract：:We have conjugated the murine monoclonal anti-CD19 antibody B43 to the tyrosine kinase inhibitor genistein to construct an effective immunoconjugate against CD19 antigen positive hematologic malignancies. The scaled-up production and purification of B43 antibody, genistein, and B43-Genistein immunoconjugate permitted ...

journal_title：Leukemia & lymphoma

authors： Myers DE,Sicheneder A,Clementson D,Dvorak N,Venkatachalam T,Sev AR,Chandan-Langlie M,Uckun FM

更新日期：1998-04-01 00:00:00

abstract：:Whether long non-coding RNA (lncRNA) single-nucleotide polymorphisms (SNPs) affect prognosis of acute myeloid leukemia (AML) remains unknown. To search the association between lncRNA SNPs and AML outcomes, thirty tagSNPs in five lncRNAs were genotyped in 313 AML patients. Survival analysis indicated that GAS5 rs558296...

journal_title：Leukemia & lymphoma

authors： Yan H,Zhang DY,Li X,Yuan XQ,Yang YL,Zhu KW,Zeng H,Li XL,Cao S,Zhou HH,Zhang W,Chen XP

更新日期：2017-08-01 00:00:00